CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation

Science Translational Medicine

Volumn 2, Issue 41, 2010, Pages

  Maury, Sébastien ^a,b   Lemoine, François M ^c,d   Hicheri, Yosr ^a,b   Rosenzwajg, Michelle ^c,d   Badoual, Cécile ^e,f   Cheraï, Mustapha ^c,d   Beaumont, Jean Louis ^g   Azar, Nabih ^c   Dhedin, Nathalie ^c   Sirvent, Anne ^h   Buzyn, Agnès ⁱ   Rubio, Marie Thérèse ⁱ   Vigouroux, Stéphane ^j   Montagne, Olivier ^a,b   Bories, Dominique ^a,b   Roudot Thoraval, Françoise ^a,b   Vernant, Jean Paul ^c   Cordonnier, Catherine ^a,b   Klatzmann, David ^c,d   Cohen, José L ^c,d  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d CNRS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^g ETABLISSEMENT FRANÇAIS DU SANG   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j HAUT LÉVÊQUE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CD4+ CD25+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DONOR LYMPHOCYTE INFUSION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TREATMENT FAILURE; ADOLESCENT; ALLOTRANSPLANTATION; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INFANT; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 77955642823     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001302     Document Type: Article

References (46)

1. P. J. Martin, J. A. Hansen, C. D. Buckner, J. E. Sanders, H. J. Deeg, P. Stewart, F. R. Appelbaum, R. Clift, A. Fefer, R. P. Witherspoon, M. S. Kennedy, K. M. Sullivan, N. Flournoy, R. Storb, E. D. Thomas, Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66, 664-672 (1985).
2. C. L. Mackall, R. E. Gress, Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy. Immunol. Rev. 157, 61-72 (1997).
3. H. J. Kolb, Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
4. M. M. Horowitz, R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringdén, C. Rozman, B. Speck, R. L. Truitt, F. E. Zwaan, M. M. Bortin, Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
5. W. D. Shlomchik, M. S. Couzens, C. B. Tang, J. McNiff, M. E. Robert, J. Liu, M. J. Shlomchik, S. G. Emerson, Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415 (1999).
6. S. Mackinnon, Donor lymphocyte infusion after allogeneic stem cell transplantation, in ASCO 2008 Educational Book (American Society of Clinical Oncology, Alexandria, VA, 2008), pp. 334-337.
7. J. L. Ferrara, J. E. Levine, P. Reddy, E. Holler, Graft-versus-host disease. Lancet 373, 1550-1561 (2009).
8. K. J. Wood, S. Sakaguchi, Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199-210 (2003).
9. V. R. Aluvihare, M. Kallikourdis, A. G. Betz, Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5, 266-271 (2004).
10. + regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. Immunol. Lett. 102, 106-109 (2006).
11. + regulatory T lymphocytes. Nat. Med. 14, 88-92 (2008).
12. hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr. Opin. Immunol. 18, 580-585 (2006).
13. + immunoregulatory T cells: New therapeutics for graft-versus-host disease. J. Exp. Med. 196, 401-406 (2002).
14. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112, 1688-1696 (2003).
15. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150 (2003).
16. + immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J. Immunol. 176, 1266-1273 (2006).
17. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
18. ClinicalTrials.gov NCT00987987.
19. M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White, S. A. Rosenberg, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
20. M. P. Colombo, S. Piconese, Regulatory T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat. Rev. Cancer 7, 880-887 (2007).
21. O. J. Finn, Cancer immunology. N. Engl. J. Med. 358, 2704-2715 (2008).
22. E. Nadal, A. Fowler, E. Kanfer, J. Apperley, J. Goldman, F. Dazzi, Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp. Hematol. 32, 218-223 (2004).
23. S. Slavin, E. Naparstek, A. Nagler, A. Ackerstein, S. Samuel, J. Kapelushnik, C. Brautbar, R. Or, Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87, 2195-2204 (1996).
24. D. L. Porter, B. L. Levine, N. Bunin, E. A. Stadtmauer, S. M. Luger, S. Goldstein, A. Loren, J. Phillips, S. Nasta, A. Perl, S. Schuster, D. Tsai, A. Sohal, E. Veloso, S. Emerson, C. H. June, A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107, 1325-1331 (2006).
25. C. Fozza, R. M. Szydlo, M. M. Abdel-Rehim, E. Nadal, J. M. Goldman, J. F. Apperley, F. Dazzi, Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: Lack of association with cell dose. Br. J. Haematol. 136, 833-836 (2007).
26. A. M. Raiola, M. T. Van Lint, M. Valbonesi, T. Lamparelli, F. Gualandi, D. Occhini, S. Bregante, C. di Grazia, A. Dominietto, M. Soracco, C. Romagnani, F. Vassallo, M. Casini, B. Bruno, F. Frassoni, A. Bacigalupo, Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: A study on 593 infusions. Bone Marrow Transplant. 31, 687-693 (2003).
27. low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion. J. Immunother. 31, 806-811 (2008).
28. reg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108, 1291-1297 (2006).
29. + regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 107, 1717-1723 (2006).
30. S. Maury, B. Salomon, D. Klatzmann, J. L. Cohen, Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 98, 3156-3158 (2001).
31. J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, T. Defor, B. R. Blazar, Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 110, 2761-2763 (2007).
32. R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, S. A. Rosenberg, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
33. D. J. Powell Jr., C. R. de Vries, T. Allen, M. Ahmadzadeh, S. A. Rosenberg, Inability to mediate prolonged reduction of regulatory T cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J. Immunother. 30, 438-447 (2007).
34. + regulatory T cells. Nat. Med. 11, 1238-1243 (2005).
35. + regulatory T cells in cancer patients. Blood 107, 2409-2414 (2006).
36. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108, 1571-1579 (2006).
37. M. A. Morse, A. C. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, T. M. Clay, Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112, 610-618 (2008).
38. K. L. Knutson, Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, M. L. Disis, IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177, 84-91 (2006).
39. M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, C. Palena, IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110, 3192-3201 (2007).
40. A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, R. Childs, Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113, 6120-6127 (2009).
41. W. H. Hallett, E. Ames, M. Alvarez, I. Barao, P. A. Taylor, B. R. Blazar, W. J. Murphy, Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. Biol. Blood Marrow Transplant. 14, 1088-1099 (2008).
42. D. Przepiorka, D. Weisdorf, P. Martin, H. G. Klingemann, P. Beatty, J. Hows, E. D. Thomas, 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 15, 825-828 (1995).
43. H. Glucksberg, R. Storb, A. Fefer, C. D. Buckner, P. E. Neiman, R. A. Clift, K. G. Lerner, E. D. Thomas, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18, 295-304 (1974).
44. B. D. Cheson, J. M. Bennett, K. J. Kopecky, T. Büchner, C. L. Willman, E. H. Estey, C. A. Schiffer, H. Doehner, M. S. Tallman, T. A. Lister, F. Lo-Coco, R. Willemze, A. Biondi, W. Hiddemann, R. A. Larson, B. Löwenberg, M. A. Sanz, D. R. Head, R. Ohno, C. D. Bloomfield, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 21, 4642-4649 (2003).
45. B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, S. T. Rosen, S. Stroobants, T. A. Lister, R. T. Hoppe, M. Dreyling, K. Tobinai, J. M. Vose, J. M. Connors, M. Federico, V. Diehl; International Harmonization Project on Lymphoma, Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579-586 (2007).
46. Acknowledgments: We thank E. Itti (Nuclear Medicine, Hôpital Henri Mondor) and B. Paulmier (Nuclear Medicine, Hôpital Européen Georges Pompidou) for providing PET imaging illustrations; N. Ortonne for help in collecting biopsy samples; L. Grégoire, C. Giverne, H. Trebeden-Negre, C. Bernard, P. Jouany, P. Maison, and V. Millul for study management; C. Pautas, M. Kuentz, I. Gaillard, T. ElGnaoui, K. Belhadj, and C. Haioun (Hematology) and M. Matignon and P. Grimbert (Nephrology) for clinical care (all in Assistance Publique-Hôpitaux de Paris); and G. Socié, O. Boyer, D. A. Landau, and C. Besson for their indispensable advice. The authors dedicate this paper to J. P. Bessège who played a major role in the achievement of this study. Funding: This study was sponsored and monitored by the Regional Clinical Research Office (Paris, France) and supported by a grant from the Programme Hospitalier de Recherche Clinique (PHRC ID, AOR04047) and from Clinigene. These sponsors had no role in study design, data analysis, data interpretation, or writing of the report. Author contributions: S.M. and J.L.C. conceived the study and obtained funding. S.M., F.M.L., M.R., M.C., O.M., F.R.-T., J.-P.V., C.C., D.K., and J.L.C. participated in study design. J.-L.B. and N.A. were responsible for donor harvesting. F.M.L., M.R., M.C., and D.K. were responsible for cellular manipulation and biological analyses. S.M., Y.H., N.D., A.S., A.B., M.-T.R., S.V., J.-P.V., and C.C. participated in patient care. C.B. was responsible for immunohistological analyses. D.B. was responsible for chimerism analyses. S.M., F.M.L., Y.H., M.R., C.B., C.C., D.K., and J.L.C. analyzed data. S.M. performed statistical analyses and wrote the initial version of the manuscript. F.M.L., Y.H., M.R., C.C., D.K., and J.L.C. contributed to the final version of the manuscript, which was approved by all the authors. Competing interests: The authors declare that they have no competing interests.